Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Preoperative risk score for access site failure in ultrasound-guided percutaneous aortic procedures.

Authors:
Patric Liang Thomas F X O'Donnell Nicholas J Swerdlow Chun Li Andy Lee Mark C Wyers Allen D Hamdan Marc L Schermerhorn

J Vasc Surg 2019 10 7;70(4):1254-1262.e1. Epub 2019 Mar 7.

Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass. Electronic address:

Objective: The factors associated with access site failure after ultrasound-guided percutaneous access for aortic endograft procedures remain poorly characterized. We developed a prediction model to risk stratify patients for access site failure.

Methods: We performed a retrospective institutional review of consecutive patients who underwent endovascular aneurysm repair (EVAR), fenestrated EVAR (FEVAR), or thoracic endovascular aortic repair (TEVAR) from 2014 to 2016. We excluded patients undergoing direct aortic access through sternotomy and patients treated with physician-modified endografts, given reporting restrictions. Our primary outcome was groin access site failure, which included bleeding and thrombosis. An 8-point risk model was created for access site failure using multivariable fractional polynomials and internally validated using bootstrapping.

Results: We identified 469 femoral arteries from 247 patients undergoing endovascular aortic repair procedures (EVAR, 75%; FEVAR, 8.0%; TEVAR, 17%). Surgeons performed percutaneous access in 97.2% of the femoral arteries, with 99.6% ultrasound use. Twenty-seven (5.9%) access site failures occurred (17 bleeding, 10 thrombosis), all treated with groin cutdown, for a successful percutaneous femoral artery access rate of 94%. Of the 215 patients with attempted bilateral percutaneous access, 90% had successful bilateral access. However, FEVAR had lower rates of successful bilateral access (FEVAR, 78%; EVAR, 91%; TEVAR, 94%; P = .03). Factors independently associated with percutaneous access site failure were femoral artery outer wall diameter (per millimeter increase: odds ratio [OR], 0.003 [0.0002-0.1]; P < .001), femoral artery stenosis >50% (OR, 22.3 [2.7-183.2]; P < .01), and urgent/emergent intervention (OR, 3.6 [1.2-11.0]; P = .03). A risk prediction model based on these criteria produced a C statistic of 0.89, a Hosmer-Lemeshow goodness of fit of 0.99, and a Brier score of 0.04. Excluding treatment for ruptured aneurysms, cutdown for access failure and planned initial groin cutdown resulted in longer postoperative lengths of stay and higher rates of access-related readmission, return to operating room, groin infection, and myocardial infarction compared with successful percutaneous access. There was no difference in major adverse events between planned initial groin cutdown and cutdown after failure; however, the small number of patients in these two comparison groups limits the statistical power to detect a difference.

Conclusions: Percutaneous ultrasound-guided access can be safely performed in almost all patients undergoing endovascular aortic procedures, but access site failures do occur. This risk score can help users select patients with high likelihood of success, identify patients who need close scrutiny with postclosure femoral duplex ultrasound, and provide patient guidance about risk of unplanned groin cutdown.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2018.12.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731168PMC
October 2019

Publication Analysis

Top Keywords

access site
32
percutaneous access
20
site failure
20
access
18
groin cutdown
16
femoral artery
12
patients undergoing
12
endovascular aortic
12
patients
10
bleeding thrombosis
8
prediction model
8
femoral arteries
8
aortic repair
8
site failures
8
planned initial
8
successful bilateral
8
successful percutaneous
8
initial groin
8
access fevar
8
undergoing endovascular
8

Similar Publications

Collagen's enigmatic, highly conserved -glycan has an essential proteostatic function.

Authors:
Rasia C Li Madeline Y Wong Andrew S DiChiara Azade S Hosseini Matthew D Shoulders

Proc Natl Acad Sci U S A 2021 Mar;118(10)

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139

Intracellular procollagen folding begins at the protein's C-terminal propeptide (C-Pro) domain, which initiates triple-helix assembly and defines the composition and chain register of fibrillar collagen trimers. The C-Pro domain is later proteolytically cleaved and excreted from the body, while the mature triple helix is incorporated into the extracellular matrix. The procollagen C-Pro domain possesses a single -glycosylation site that is widely conserved in all the fibrillar procollagens across humans and diverse other species. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) through non-specialist providers and telemedicine: a study protocol for a non-inferiority randomized controlled trial.

Authors:
D R Singla S E Meltzer-Brody R K Silver S N Vigod J J Kim L M La Porte P Ravitz C E Schiller N Schoueri-Mychasiw S D Hollon A Kiss D Clark A K Dalfen S Dimidjian B N Gaynes S R Katz A Lawson M Leszcz R G Maunder B H Mulsant K E Murphy J A Naslund M L Reyes-Rodríguez A M Stuebe C-L Dennis V Patel

Trials 2021 Mar 5;22(1):186. Epub 2021 Mar 5.

Department of Obstetrics & Gynecology, School of Medicine, University of North Carolina, Chapel Hill, USA.

Background: Depression and anxiety impact up to 1 in 5 pregnant and postpartum women worldwide. Yet, as few as 20% of these women are treated with frontline interventions such as evidence-based psychological treatments. Major barriers to uptake are the limited number of specialized mental health treatment providers in most settings, and problems with accessing in-person care, such as childcare or transportation. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Authors:
Eugenia Oviedo-Joekes Scott MacDonald Charles Boissonneault Kelli Harper

Subst Abuse Treat Prev Policy 2021 Mar 5;16(1):22. Epub 2021 Mar 5.

Providence Health Care, Providence Crosstown Clinic, 84 West Hastings Street, Vancouver, BC, V6B 1G6, Canada.

Background: In North America the opioid poisoning crisis currently faces the unprecedented challenges brought by the COVID-19 pandemic, further straining people and communities already facing structural and individual vulnerabilities. People with opioid use disorder (OUD) are facing unique challenges in response to COVID-19, such as not being able to adopt best practices (e.g. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Exploring and understanding HCV patient journeys- HEPCARE Europe project.

Authors:
Shannon Glaspy Gordana Avramovic Tina McHugh Cristiana Oprea Julian Surey Irina Ianache Juan Macías Alistair Story Walter Cullen John S Lambert

BMC Infect Dis 2021 Mar 5;21(1):239. Epub 2021 Mar 5.

Consultant in Infectious Diseases, Medicine and Sexual Health, Mater Misericordiae University Hospital, Dublin 7, Ireland.

Background: Hepatitis C Virus (HCV) is a leading cause for chronic liver diseases worldwide. The European Union and World Health Organization aspire to eliminate HCV by 2030. However, among at-risk populations, including, homeless people, prisoners and People Who Inject Drugs, access to diagnosis and treatment is challenging. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry.

Authors:
Manuel Almendro-Delia Álvaro Izquierdo-Bajo Luis Madrona-Jiménez Emilia Blanco-Ponce Tania Seoane-García Manuel García-Del Río Jesús Carmona-Carmona J A Arboleda Sánchez Juan Carlos Rodríguez Yáñez José Manuel Soto Blanco Isabel Fernández García José Antonio Castillo Caballero Rafael J Hidalgo-Urbano Juan Carlos García-Rubira

Int J Cardiol 2021 Mar 2. Epub 2021 Mar 2.

Acute Cardiovascular Care Unit, Hospital Universitario Virgen Macarena, Seville, Spain.

Background: Fondaparinux is thought to have the most favorable risk-benefit profile among all anticoagulants in non-ST-elevation acute coronary syndrome (NSTE-ACS). However, conflicting findings exist whether this holds true in current clinical practice. We aimed to assess the net clinical benefit of fondaparinux versus enoxaparin in the contemporary management of NSTE-ACS. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap